Review of the In Vitro Microbiological Activity of Mecillinam Against Common Uropathogens in Uncomplicated Urinary Tract Infection: Focus on Resistant Pathogens
Open Forum Infectious Diseases · 03.06.2024 · 11 (6)
DOI: 10.1093/ofid/ofae296 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Open Forum Infectious Diseases, online erschienen am 24.05.2024. Verfasst von Thomas P Lodise und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Practice, Albany College of Pharmacy and Health Sciences, Albany, New York, USA. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Antimicrobial resistance in uropathogens commonly causing urinary tract infections (UTIs) is a growing problem internationally. Pivmecillinam, the oral prodrug of mecillinam, has been used for over 40 years, primarily in Northern Europe and Canada. It is recommended in several countries as a first-line agent for the treatment of uncomplicated UTIs (uUTIs) and is now approved in the United States. We performed a structured literature search to review the available evidence on susceptibility of common uUTI-causing uropathogens to mecillinam. Among 38 studies included in this literature review, susceptibility rates for Escherichia coli to mecillinam—including resistant phenotypes such as extended-spectrum β-lactamase–producing E. coli—exceed 90% in most studies. High rates of susceptibility were also reported among many other uropathogens including Klebsiella spp., Enterobacter spp., and Citrobacter spp. In the current prescribing climate within the United States, pivmecillinam represents a viable first-line treatment option for patients with uUTI.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacy Practice, Albany College of Pharmacy and Health Sciences, Albany, New York, USA.
- Department of Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA.
- Maxel Consulting ApS, Jyllinge, Denmark.
- Department of Clinical Microbiology, Central Hospital, Växjö, Sweden.
ORCID-Profile: Thomas P Lodise, Keith S Kaye
Zitieren
APA
Lodise, T. P., Kaye, K. S., Santerre Henriksen, A., & Kahlmeter, G. (2024). Review of the In Vitro Microbiological Activity of Mecillinam Against Common Uropathogens in Uncomplicated Urinary Tract Infection: Focus on Resistant Pathogens. Open Forum Infectious Diseases, 11(6). https://doi.org/10.1093/ofid/ofae296
Vancouver
Lodise TP, Kaye KS, Santerre Henriksen A, Kahlmeter G. Review of the In Vitro Microbiological Activity of Mecillinam Against Common Uropathogens in Uncomplicated Urinary Tract Infection: Focus on Resistant Pathogens. Open Forum Infectious Diseases. 2024;11(6). doi:10.1093/ofid/ofae296
BibTeX
@article{Lodise2024,
author = {Lodise, Thomas P and Kaye, Keith S and Santerre Henriksen, Anne and Kahlmeter, Gunnar},
title = {Review of the In Vitro Microbiological Activity of Mecillinam Against Common Uropathogens in Uncomplicated Urinary Tract Infection: Focus on Resistant Pathogens},
journal = {Open Forum Infectious Diseases},
year = {2024},
volume = {11},
number = {6},
doi = {10.1093/ofid/ofae296}
}
EUVIMED